I
n vivo imaging enables us to peer deeply within living subjects and is producing tremendous opportunities both for the study of cancer biology and clinical diagnostics. 1 Rapid advances in fluorescent imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and ultrasound imaging promise to translate the insights from basic science at the single-cell level to clinical application. Among these imaging modalities, MRI is among the most prominently used in medical diagnostics. Metal-based contrast materials have been widely adopted to clearly visualize the functional architecture of physiological structures. At present, Johnson and co-workers exploit a potential substitute in the form of nitroxide-based macromolecular contrast agents with unprecedented transverse relaxivity and stability for MRI of tumors.
2
MRI is a noninvasive, nonionizing modality offering anatomical, physiological, and even molecular information within the bodies of living subjects. 1 Standard MRI inherently suffers from low sensitivity stemming from the mechanism of signal detection which typically measures the relaxation rates of water protons. Contrast agents are thus used to alter the water proton relaxation rates and highlight anatomical and pathological features in the imaged tissues by enhancing images contrast (Figure 1 Introducing a new class of exceptionally stable, biocompatible nitroxide magnetic resonance imaging contrast agents with unprecedented transverse relaxivity as a potential substitute to current metal-based contrast agents.
First Reactions
PEGylated branched-bottlebrush polymers, demonstrating in 2014 that increasing the macromolecular size and chex density leads to increases in both r 1 and r 2 . 10 But the problem of their poor in vivo stability has not been well resolved by now.
To address these problems, Johnson and co-workers have systematically investigated and uncovered a new class of nitroxide nanoparticlesbrush-arm star polymer ORCAs (BASP-ORCAs) (Figure 2 ). These nanoparticles contain a dense layer of chex nitroxides bound in an interlayer between a hydrophilic poly(ethylene glycol) (PEG) shell and a rigid poly(acetal) core. The authors discovered that the distinct cross-linked multilayer nanostructure resulted in a shielded and dense nitroxide layer, providing dramatic increases in relaxivity values (44 times higher than common nitroxides). In addition, the average molecular r 1 and r 2 values for BASP-ORCAs are even greater than those for the commonly used FDA-approved Gd-based contrast agent Magnevist and iron-based nanoparticles such as Feraheme. The rigid chex environment in the BASP-ORCAs contributes to the low rate of chex reduction, which allows for tumor MRI in mice up to 20 h after tail-vein injection. Among these metal-free MRI contrast agents, nitroxide ORCAs are in principle most likely to translate to the clinic since they acquire an MRI signal using standard water relaxation mechanisms.
The rigid chex environment in the BASP-ORCAs contributes to the low rate of chex reduction, which allows for tumor MRI in mice up to 20 h after tail-vein injection.
These features combine to allow the BASP-ORCAs to perform with unprecedented transverse relaxivity, exceptional stability, and good in vivo biocompatibility. 
